{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:10:35Z","timestamp":1778170235414,"version":"3.51.4"},"reference-count":65,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stead Scholarship","award":["Duke Internal-NA"],"award-info":[{"award-number":["Duke Internal-NA"]}]},{"name":"Office of Physician Scientist Development","award":["Duke Internal-NA"],"award-info":[{"award-number":["Duke Internal-NA"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-20-1-0346"],"award-info":[{"award-number":["W81XWH-20-1-0346"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-21-2-0031"],"award-info":[{"award-number":["W81XWH-21-2-0031"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA238217-01A1\/02S1"],"award-info":[{"award-number":["R01CA238217-01A1\/02S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The contribution of B cells to antitumor immunity remains controversial, with studies reporting varied effects across cancer types. Even less is known about the role of the endogenous humoral response, including when tumor-elicited antibodies are protective, when they are deleterious, and how they might be modulated to influence antitumor immunity. Critically, it remains unclear whether specific antigenic features govern the efficacy of humoral immune responses against cancer. We aim to define the conditions under which endogenous antibodies mediate antitumor immunity and to leverage these principles to improve neoantigen-directed immunotherapies, including cancer vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a pan-cancer analysis of The Cancer Genome Atlas (TCGA) to assess associations between intratumoral IgG and clinical outcomes. Using syngeneic mouse tumor models expressing membrane or cytoplasmic neoantigens, we examined how antigen localization influences endogenous antibody responses. We evaluated strategies to enhance humoral immunity via cytokine and chemokine modulation and assessed antibody responses in the context of cancer vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our pan-cancer TCGA analysis revealed marked heterogeneity in the prognostic impact of intratumoral IgG. In vivo, expression of membrane-localized, but not cytoplasmic, neoantigens drove potent class-switched IgG responses, activated myeloid cells, and restricted tumor growth independently of CD8 T cells. Notably, membrane-restricted antigen expression was sufficient to convert tumor types such as colorectal cancer, where IgG correlates with poor prognosis, into settings in which antibodies mediate tumor suppression. These effects required CD4 T-cell help, antigen-specific IgG, and Fc receptor engagement. Enhancing B-cell recruitment (C-X-C motif chemokine ligand 13) or B-cell help (interleukin (IL)-21) further amplified antibody-mediated tumor control, with co-expression providing the strongest benefit. Finally, we establish that antigen localization dictates vaccine efficacy: the point-mutated trophoblast cell-surface antigen 2 (Trop2) T256R, which exhibits impaired membrane localization and reduced antibody binding relative to wild-type Trop2, failed to elicit comparable vaccine-induced tumor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings identify antigen subcellular localization as a key regulator of endogenous antibody-mediated antitumor immunity and cancer vaccine efficacy, providing a mechanistic framework for leveraging humoral immunity in immunotherapeutic strategies. CXCL13 and IL-21 emerge as candidate approaches to selectively enhance antibody-mediated tumor control in settings where membrane-bound antigens are present.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014671","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:32Z","timestamp":1778166932000},"page":"e014671","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy"],"prefix":"10.1136","volume":"14","author":[{"given":"Sirajbir S","family":"Sodhi","sequence":"first","affiliation":[{"name":"Duke University School of Medicine, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S","family":"Wang","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-8332","authenticated-orcid":false,"given":"David T","family":"Severson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey V","family":"Ragusa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Trotter","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chung","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4770","authenticated-orcid":false,"given":"Herbert Kim","family":"Lyerly","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"},{"name":"Department of Integrative Immunobiology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6549-8207","authenticated-orcid":false,"given":"Zachary Conrad","family":"Hartman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina, USA"},{"name":"Department of Integrative Immunobiology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026050708152062000_14.5.e014671.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30517-X"},{"key":"2026050708152062000_14.5.e014671.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30254-7"},{"key":"2026050708152062000_14.5.e014671.3","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.medj.2025.100647","article-title":"UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial","volume":"6","author":"Brandt","year":"2025","journal-title":"Med"},{"key":"2026050708152062000_14.5.e014671.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-016-0264-5","article-title":"pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens","volume":"8","author":"Hundal","year":"2016","journal-title":"Genome Med"},{"key":"2026050708152062000_14.5.e014671.5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0464"},{"key":"2026050708152062000_14.5.e014671.6","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw019"},{"key":"2026050708152062000_14.5.e014671.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005848","article-title":"Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab","volume":"11","author":"Routh","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050708152062000_14.5.e014671.8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-025-04177-6","article-title":"Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade","volume":"32","author":"Gonzalez-Kozlova","year":"2026","journal-title":"Nat Med"},{"key":"2026050708152062000_14.5.e014671.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.11.007"},{"key":"2026050708152062000_14.5.e014671.10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature14424","article-title":"Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity","volume":"521","author":"Carmi","year":"2015","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803773"},{"key":"2026050708152062000_14.5.e014671.12","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.4049\/jimmunol.142.10.3702","article-title":"Low natural antibody and low in vivo tumor resistance, in xid-bearing B-cell deficient mice","volume":"142","author":"Chow","year":"1989","journal-title":"J Immunol"},{"key":"2026050708152062000_14.5.e014671.13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69713","article-title":"Redefining innate natural antibodies as important contributors to anti-tumor immunity","volume":"10","author":"Rawat","year":"2021","journal-title":"Elife"},{"key":"2026050708152062000_14.5.e014671.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200447"},{"key":"2026050708152062000_14.5.e014671.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65579"},{"key":"2026050708152062000_14.5.e014671.16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","article-title":"B-cell-specific checkpoint molecules that regulate anti-tumour immunity","volume":"619","author":"Bod","year":"2023","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-627"},{"key":"2026050708152062000_14.5.e014671.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.09.003"},{"key":"2026050708152062000_14.5.e014671.19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-10-122","article-title":"Prediction of disease-related mutations affecting protein localization","volume":"10","author":"Laurila","year":"2009","journal-title":"BMC Genomics"},{"key":"2026050708152062000_14.5.e014671.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"key":"2026050708152062000_14.5.e014671.21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao","year":"2019","journal-title":"JCI Insight"},{"key":"2026050708152062000_14.5.e014671.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"2026050708152062000_14.5.e014671.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.004"},{"key":"2026050708152062000_14.5.e014671.24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2767-9764.CRC-24-0062","article-title":"Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent \u201cNoGlow\u201d Mice","volume":"4","author":"Trotter","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026050708152062000_14.5.e014671.25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.virol.2006.08.041","article-title":"Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells","volume":"358","author":"Hartman","year":"2007","journal-title":"Virology (Auckl)"},{"key":"2026050708152062000_14.5.e014671.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2549"},{"key":"2026050708152062000_14.5.e014671.27","unstructured":"Liu J , Lichtenberg T , Hoadley KA , et al . Data from: an integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. NCI Genomic Data Commons; 2018. Available: https:\/\/gdc.cancer.gov\/about-data\/publications\/PanCan-Clinical-2018"},{"key":"2026050708152062000_14.5.e014671.28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12"},{"key":"2026050708152062000_14.5.e014671.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2026050708152062000_14.5.e014671.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790119","article-title":"A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires","volume":"12","author":"Yu","year":"2021","journal-title":"Front Immunol"},{"key":"2026050708152062000_14.5.e014671.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.038"},{"key":"2026050708152062000_14.5.e014671.32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx8303","article-title":"B cell-reactive neoantigens boost antitumor immunity","volume":"11","author":"Kim","year":"2025","journal-title":"Sci Adv"},{"key":"2026050708152062000_14.5.e014671.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.02.012"},{"key":"2026050708152062000_14.5.e014671.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0507"},{"key":"2026050708152062000_14.5.e014671.35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522"},{"key":"2026050708152062000_14.5.e014671.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101145","article-title":"Membrane-localized neoantigens predict the efficacy of cancer immunotherapy","volume":"4","author":"Goldberger","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026050708152062000_14.5.e014671.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8"},{"key":"2026050708152062000_14.5.e014671.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02039","article-title":"Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer","volume":"11","author":"Lin","year":"2020","journal-title":"Front Immunol"},{"key":"2026050708152062000_14.5.e014671.39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127882","article-title":"New epitopes in ovalbumin provide insights for cancer neoepitopes","volume":"5","author":"Karandikar","year":"2019","journal-title":"JCI Insight"},{"key":"2026050708152062000_14.5.e014671.40","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp112"},{"key":"2026050708152062000_14.5.e014671.41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091777"},{"key":"2026050708152062000_14.5.e014671.42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/35876","article-title":"A B-cell-homing chemokine made in lymphoid follicles activates Burkitt\u2019s lymphoma receptor-1","volume":"391","author":"Gunn","year":"1998","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.028"},{"key":"2026050708152062000_14.5.e014671.44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"2026050708152062000_14.5.e014671.45","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B"},{"key":"2026050708152062000_14.5.e014671.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0257-x"},{"key":"2026050708152062000_14.5.e014671.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2026050708152062000_14.5.e014671.48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2026050708152062000_14.5.e014671.50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2024.6872","article-title":"Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial","volume":"11","author":"Dieci","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026050708152062000_14.5.e014671.51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","article-title":"Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2\/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials","volume":"9","author":"Fernandez-Martinez","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026050708152062000_14.5.e014671.52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41416-018-0266-8","article-title":"A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis","volume":"119","author":"Sj\u00f6berg","year":"2018","journal-title":"Br J Cancer"},{"key":"2026050708152062000_14.5.e014671.53","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-016-0232-0","article-title":"Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer","volume":"9","author":"Lundgren","year":"2016","journal-title":"J Ovarian Res"},{"key":"2026050708152062000_14.5.e014671.54","doi-asserted-by":"crossref","first-page":"113002","DOI":"10.1016\/j.intimp.2024.113002","article-title":"CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer","volume":"141","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026050708152062000_14.5.e014671.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00466-1"},{"key":"2026050708152062000_14.5.e014671.56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","article-title":"Defining HPV-specific B cell responses in patients with head and neck cancer","volume":"597","author":"Wieland","year":"2021","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.57","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0236"},{"key":"2026050708152062000_14.5.e014671.58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8797"},{"key":"2026050708152062000_14.5.e014671.59","doi-asserted-by":"crossref","DOI":"10.3390\/antib9040064","article-title":"Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"2026050708152062000_14.5.e014671.60","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"2026050708152062000_14.5.e014671.61","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.650.65.2","article-title":"Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase","volume":"65","author":"Montgomery","year":"2005","journal-title":"Cancer Res"},{"key":"2026050708152062000_14.5.e014671.62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature New Biol"},{"key":"2026050708152062000_14.5.e014671.63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1369743","article-title":"Therapeutic potential of interleukin-21 in cancer","volume":"15","author":"Isvoranu","year":"2024","journal-title":"Front Immunol"},{"key":"2026050708152062000_14.5.e014671.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.036"},{"key":"2026050708152062000_14.5.e014671.65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-024-01751-w","article-title":"Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain","volume":"21","author":"Bang","year":"2025","journal-title":"Nat Chem Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:15:38Z","timestamp":1778166938000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014671"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014671","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}